New updates have been reported about 9amHealth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
9amHealth has secured $26 million in Series B funding led by Define Ventures, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures, to accelerate expansion of its AI-enabled virtual specialty care platform. The company, which has already generated more than $50 million in projected medical and pharmacy savings for two Fortune 100 employers, plans to move beyond cardiometabolic conditions into additional high-cost chronic diseases that drive up to 70% of employer pharmacy spend.
Building on its existing infrastructure for obesity, diabetes, hypertension, and hyperlipidemia, 9amHealth will use the capital to scale clinical operations, technology, and AI-enabled workflows that support complex chronic care at enterprise level. CEO and Co-Founder Frank Westermann said the company’s ability to combine specialized clinical care, continuous engagement, labs, and medication management with AI-driven workflows underpins its ability to deliver cost savings while managing demand for expensive therapies such as GLP-1 drugs. Lynne O’Keefe, Founder and Managing Partner at Define Ventures, will join the board, signaling investor confidence that 9amHealth can help employers, health plans, and PBMs contain their fastest-growing cost categories by virtualizing specialty care for their most expensive patient populations.